Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BMS-986435 Tablet Formulations in Healthy Adults
NCT06577259Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-986435 in heart failure with preserved ejection fraction (HFpEF) and hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 105 days, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration up to 105 days and 1 more. Started Sep 2024; status: completed.
02
Drugs
BMS-986435
03
Conditions
heart failure with preserved ejection fraction (HFpEF)hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06577259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577259.